These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16425989)

  • 1. Antiangiogenesis: a possible treatment option for prostate cancer?
    Longoria RL; Cox MC; Figg WD
    Clin Genitourin Cancer; 2005 Dec; 4(3):197-202. PubMed ID: 16425989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis as a strategic target for prostate cancer therapy.
    Li Y; Cozzi PJ
    Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis and prostate cancer: important laboratory and clinical findings.
    Cox MC; Permenter M; Figg WD
    Curr Oncol Rep; 2005 May; 7(3):215-9. PubMed ID: 15847713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiogenesis and anti-angiogenic therapy in prostate cancer.
    Mukherji D; Temraz S; Wehbe D; Shamseddine A
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):122-31. PubMed ID: 23375349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiogenesis inhibitors in the treatment of prostate cancer.
    Adesunloye BA; Karzai FH; Dahut WL
    Chem Immunol Allergy; 2014; 99():197-215. PubMed ID: 24217611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenesis: the fifth cancer treatment modality?
    Camp-Sorrell D
    Oncol Nurs Forum; 2003; 30(6):934-44. PubMed ID: 14603351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.
    Ryan CJ; Lin AM; Small EJ
    Urol Oncol; 2006; 24(3):250-3. PubMed ID: 16678059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of angiogenesis in prostate development and the pathogenesis of prostate cancer.
    Hrouda D; Nicol DL; Gardiner RA
    Urol Res; 2003 Feb; 30(6):347-55. PubMed ID: 12599013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic targeting of the tumor vasculature.
    Tozer GM; Bicknell R
    Semin Radiat Oncol; 2004 Jul; 14(3):222-32. PubMed ID: 15254865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor angiogenesis in melanoma.
    Marneros AG
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):431-46, vii-viii. PubMed ID: 19464595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of angiogenesis inhibitors in prostate cancer.
    Aragon-Ching JB; Dahut WL
    Cancer J; 2008; 14(1):20-5. PubMed ID: 18303479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study.
    Lennernäs B; Albertsson P; Damber JE; Norrby K
    APMIS; 2004 Mar; 112(3):201-9. PubMed ID: 15153162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate.
    Colombel M; Filleur S; Fournier P; Merle C; Guglielmi J; Courtin A; Degeorges A; Serre CM; Bouvier R; Clézardin P; Cabon F
    Cancer Res; 2005 Jan; 65(1):300-8. PubMed ID: 15665307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches.
    van Moorselaar RJ; Voest EE
    Mol Cell Endocrinol; 2002 Nov; 197(1-2):239-50. PubMed ID: 12431818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenesis therapeutic strategies in prostate cancer.
    Macpherson GR; Ng SS; Lakhani NJ; Price DK; Venitz J; Figg WD
    Cancer Metastasis Rev; 2002; 21(1):93-106. PubMed ID: 12400998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis and cancer: recent advances.
    Cáceres W; González S
    P R Health Sci J; 2003 Jun; 22(2):149-51. PubMed ID: 12866139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005?
    Raben D; Ryan A
    Clin Lung Cancer; 2005 Nov; 7(3):175-9. PubMed ID: 16354311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer.
    Wang C; Tao W; Wang Y; Bikow J; Lu B; Keating A; Verma S; Parker TG; Han R; Wen XY
    Eur Urol; 2010 Sep; 58(3):418-26. PubMed ID: 20605315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extracellular environment.
    Gagne P; Akalu A; Brooks PC
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):129-40. PubMed ID: 14748663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.